Skip to main content

Table 4 Standardized Incidence Ratios for subsequent primary sarcoma according to type of first cancer and radiotherapy, SEER 9 1973-2008

From: Sarcoma risk after radiation exposure

 

Bone sarcoma

Soft tissue sarcoma

 

Radiotherapy

No radiotherapy

Radiotherapy

No radiotherapy

1st cancer type

Obs

SIR

Obs

SIR

Obs

SIR

Obs

SIR

Oral Cavity and Pharynx

9

7.61*

1

0.49

12

1.95*

8

0.75

Rectum and Anus

6

5.15*

6

1.77

12

1.82

18

0.96

Larynx

2

1.62

2

3.80

6

0.87

3

1.06

Lung and Bronchus

0

0.00

4

1.48

12

3.44*

19

1.30

Female Breast

21

2.59*

21

1.28

104

2.67*

101

1.29*

Cervix Uteri

6

6.62*

1

0.71

10

2.38*

6

1.04

Corpus Uteri

12

3.96*

3

0.62

27

1.89*

29

1.25

Ovary

3

13.99*

2

1.45

6

6.25*

9

1.44

Prostate

8

1.09

19

1.38

89

1.69*

97

1.05

Testis

0

0.00

0

0.00

9

2.60*

8

2.78*

Brain and CNS

3

10.47*

0

0.00

4

3.66*

3

3.44

Thyroid

4

4.12*

2

0.91

11

2.63*

10

1.04

Hodgkin Lymphoma

3

4.28

3

6.37*

22

8.71*

7

3.72*

Non-Hodgkin Lymphoma

10

9.00

7

2.92*

11

1.96

17

1.36

Leukemia

1

17.60

5

3.09*

1

4.17

10

1.16

  1. *p < 0.05. Obs-observed number of subsequent primary sarcomas. SIR-standardized incidence ratio. Analysis includes adulthood (age 20–79 years at diagnosis) 1+ year survivors of the specified 1st cancer type. Follow-up for second primary bone or soft tissue sarcoma continued to age 85 years. Patients with unknown radiotherapy were excluded.
Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329